This study is looking at a new way to treat newly diagnosed glioblastoma multiforme (GBM), a type of brain tumor. It combines two chemotherapy drugs, capecitabine and temozolomide. Capecitabine is an oral chemotherapy already used for other cancers. The study wants to see if adding capecitabine to your monthly temozolomide treatment is safe and tolerable after you've completed initial radiation and temozolomide. Researchers also want to find out if this combination helps patients respond to treatment for a longer time compared to temozolomide alone, which is the current standard treatment. You may be able to join if you are 18-74 years old, have a new diagnosis of GBM, and have finished your initial chemo-radiation but haven't started monthly temozolomide yet. The study aims to measure how long patients live without their cancer growing (progression-free survival) and overall survival. The current status of this study is unclear.

Study design

This is an interventional study with a planned enrollment of 67 participants. It is testing the combination of capecitabine and temozolomide.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will track progression-free survival at 6 months and overall survival at 4 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.